Requests that the FDA further and more deeply and critically investigate the trial conduct of the ORATORIO trial (the sole pivotal trial of ocrelizumab/Ocrevus for PPMS) in light of the FDAs request to withdraw their previous approval of Tavneos
🏛 Food and Drug Administration (FDA)FDA-2026-P-4732
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.